{"filing":{"accession_number":"0001129928-26-000037","cik":"0001129928","ticker":"ONCY","company_name":"ONCOLYTICS BIOTECH INC","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"oncy-20260601.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000037/oncy-20260601.htm"},"events":[{"id":7738,"run_id":6799,"accession_number":"0001129928-26-000037","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Oncolytics disclosed initial preclinical data for pelareorep in combination with RAS inhibitor modalities and announced plans for additional studies. For a biotech company, preclinical data announcements and new study plans represent material developments in the clinical pipeline that would affect investor assessment of the company's prospects, though the disclosure does not fit the more specific event categories (not an earnings release, executive change, M\u0026A, impairment, or litigation).","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3056,"accession_number":"0001129928-26-000037","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Oncolytics disclosed initial preclinical data for pelareorep in combination with RAS inhibitor modalities and announced plans for additional studies. For a biotech company, preclinical data announcements and new study plans represent material developments in the clinical pipeline that would affect investor assessment of the company's prospects, though the disclosure does not fit the more specific event categories (not an earnings release, executive change, M\u0026A, impairment, or litigation).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:17:54.523071+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3056,"accession_number":"0001129928-26-000037","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Oncolytics disclosed initial preclinical data for pelareorep in combination with RAS inhibitor modalities and announced plans for additional studies. For a biotech company, preclinical data announcements and new study plans represent material developments in the clinical pipeline that would affect investor assessment of the company's prospects, though the disclosure does not fit the more specific event categories (not an earnings release, executive change, M\u0026A, impairment, or litigation).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:17:54.523071+00:00","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-06-01"}]}